Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.59 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.49 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.63 |
| ▸ | DHODH | Q02127 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9597551 | 1.00 | PDE10A (0.63) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| SCHEMBL29377848 | 0.98 | PDE10A (0.66) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| SCHEMBL641899 | 0.98 | PDE10A (0.66) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| Water SCHEMBL2991911 | 0.95 | PDE10A (0.63) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| Iodide SCHEMBL8029606 | 0.95 | PDE10A (0.63) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| Iodide SCHEMBL8029601 | 0.95 | PDE10A (0.63) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| SCHEMBL7516228 | 0.88 | PDE10A (0.56) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7534602 | 0.87 | CYP2C19 (0.56) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| SCHEMBL9056825 | 0.86 | PDE10A (0.54) | PDE10ADHODHLMNAKMT2AALDH1A1 | |
| SCHEMBL9056820 | 0.86 | PDE10A (0.54) | PDE10ADHODHLMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096599-A1 | MEASUREMENT OF MULTIPLE ANALYTES USING ACRIDINIUM LABELS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20110082279-A1 | Chemiluminescent Compounds | GEN-PROBE INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1658503-B1 | CHEMILUMINESCENT COMPOUNDS | MOLECULAR LIGHT TECH RES LTD (GB) | 2009-11-18 | — | — | EP | disclosed |
| EP-1781816-A4 | COMPOSITIONS AND METHODS FOR RELEASING NUCLEIC ACIDS FROM SOLID PHASE BINDING MATERIALS | NEXGEN DIAGNOSTICS LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1789578-A4 | CLEAVABLE SOLID PHASES FOR ISOLATING NUCLEIC ACIDS | NEXGEN DIAGNOSTICS LLC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-7332354-B2 | Compounds for chemiluminescense procedures | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1781808-A4 | METHODS OF USING CLEAVABLE SOLID PHASES FOR ISOLATING NUCLEIC ACIDS | LUMIGEN INC (US) | 2007-08-29 | — | — | EP | disclosed |
| CN-101027411-A | Compositions and methods for releasing nucleic acids from solid phase binding materials | LUMIGEN INC (US) | 2007-08-29 | — | — | CN | disclosed |
| CN-101018871-A | Cleavable solid phases for isolating nucleic acids | LUMIGEN INC (US) | 2007-08-15 | — | — | CN | disclosed |
| CN-101018870-A | Methods of using cleavable solid phases for isolating nucleic acids | LUMIGEN INC (US) | 2007-08-15 | — | — | CN | disclosed |
| US-5702887-A | BENZ(B)ACRIDINIUM-12-CARBOXYLATE COMPOUNDS | CHIRON DIAGNOSTICS CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| US-5491072-A | N-alkylacridan carboxyl derivatives useful for chemiluminescent detection | LUMIGEN, INC. (US) | 1996-02-13 | — | — | US | disclosed |
| US-5395752-A | Detecting emission signals of conjugates of angular or linear four ring or three ring acridinium compounds | CIBA CORNING DIAGNOSTICS CORP. (US) | 1995-03-07 | — | — | US | disclosed |
| WO-1994026927-A1 | NOVEL N-ALKYLACRIDAN CARBOXYL DERIVATIVES USEFUL FOR CHEMILUMINESCENT DETECTION | LUMIGEN, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0625510-A2 | Novel N-alkylacridan carboxyl derivatives useful for chemiluminescent detection | LUMIGEN, INC. (US) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994021823-A1 | LONG EMISSION WAVELENGTH CHEMILUMINESCENT COMPOUNDS AND THEIR USE IN TEST ASSAYS | CIBA CORNING DIAGNOSTICS CORP. (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0617288-A2 | Long emission wavelength chemiluminescent compounds and their use in test assays | CIBA-GEIGY AG (CH) | 1994-09-28 | — | — | EP | disclosed |
| EP-0511366-A1 | CHEMILUMINESCENT COMPOUNDS | BECKMAN INSTRUMENTS, INC. (US) | 1992-11-04 | — | — | EP | disclosed |
| WO-1992009580-A1 | CHEMILUMINESCENT COMPOUNDS | BECKMAN INSTRUMENTS, INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| EP-0407816-A2 | Base modified nucleosides | ABBOTT LABORATORIES (US) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082279-A1 | Chemiluminescent Compounds | CBR3, LTC4S, CBR1 | GLA 608/4885GAA 1808/4885PRKD3 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.